# MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation

> **NCT02250300** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mehdi Hamadani** · enrollment: 68 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** MLN9708 (2.3 mg)
- **DRUG:** MLN9708 (4.0 mg)
- **DRUG:** MLN9708 (3.0 mg)

## Key facts

- **NCT ID:** NCT02250300
- **Lead sponsor:** Mehdi Hamadani
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-19
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-06
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250300, "MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02250300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*